European Psychiatry - Volume 33 - March 2016

508 / 812

S504 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
Conclusion Augmentation strategy is often used in patients with
MDD. There is no significant difference in the use combination ther-
apy based on gender and age.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV485
The Mini-Spadin, an efficient alternate
to Spadin in the depression treatment
M. Borsotto ∗ jillani , C. Devader , C. Heurteaux , J. Mazella
IPMC, UMR7275, Valbonne, France
∗ Corresponding author.
Objectives We previously discovered spadin as a newantidepres-
sant drug concept. Spadin exerts its antidepressant actions on the
TREK-1 potassium channel, a new antidepressant (AD) target. We
have shown that spadin acts more rapidly in comparison to other
ADs. We have pointed out that spadin induced neurogenesis after
only 4-day treatments. We have demonstrated that spadin did not
display side effects at the cardiac level and on TREK-1 controlled
functions such as stroke, epilepsy or pain.
Objectives With the final goal to make spadin a drug for human
clinic, our objective was to find analogs of spadin demonstrating a
better affinity or a better in vivo stability or both.
Methods Several analogs of spadin were synthesized. Their abil-
ity to block the TREK-1 channel activity were first tested by
electrophysiology on HEK293 cells stably transfected with TREK-1
channels. AD effects were measured by using the forced swim test
and the novelty suppressed feeding test. Neurogenesis was inves-
tigated by measuring the expression level of the synaptic protein
PSD-95 in in vitro cultured neurons.
Results Our data allow us to identify a shortened spadin, called
mini-spadin, that displayed the same AD properties as spadin and a
400 fold increase in the TREK-1 affinity. Mini-spadin increased the
synaptogenesis marker PSD95 levels after only 24 hours of treat-
ment, suggesting that like spadin, mini-spadin was able to induce
neurogenesis and synaptogenesis.
Conclusions Even if further experiments are required, the mini-
spadin appears to be more efficient than spadin offering a very
promising alternate to spadin as human drug.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV486
Short-term study in patients treated
with desvenlafaxine
M.P. Calvo Rivera ∗, L. Aguado Bailón , B. Girela Serrano
1 San Cecilio University Hospital, Psychiatry Service, Granada, Spain
2 Santa Ana Hospital, Psychiatry Service, Motril-Granada, Spain
∗ Corresponding author.
Introduction Desvenlafaxine is an antidepressant inhibitor of the
reuptake of norepinephrine and serotonin (SNRI). Several publica-
tions support its efficacy in reducing depressive symptoms in the
short term.
Objectives The objective of this paper is to estimate the effect of
short-term (12 weeks) of patients with depressive disorder treated
with desvenlafaxine.
Methodology This is a prospective observational study track-
ing a cohort of outpatients with depressive disorder treated with
Desvenlafaxine for three months. To accomplish our goal we used
the Montgomery-Asberg scale performing three measurements
(baseline, one month and two months after initiate the treatment).
The size of our sample was 24 patients.
Results We found that in about 80% of patients the treatment
was effective, no significant differences in relation to sex, age or
treatment dose were reported. Regarding the severity of the symp-
toms, in the initial assessment 16% of the patients had a mild
depressive episode, 70% a moderate episode and about 12% had a
severe episode; while in the last evaluation, almost 46% of patients
were in recovery, nearly 42% had mild symptoms, 8% moderate
symptoms and only 4% had mild symptoms.
Conclusion We can conclude that the treatment with Desven-
lafaxine has been effective at improving in the short-term the
depressive disorder, independently of gender, age and dose admin-
istered.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV487
Depression and ischemic heart
disease: The role of the endogenous
stress response system
V. Caivano , F. Monteleone , R. Farina , D. Nunziata ,
G. Cascino ∗, A. De Rosa , G. D’Agostino , L. Steardo ,
F. Piscione , P. Monteleone
1 University of Salerno, Department of Medicine and Surgery, Salerno,
Italy
2 AOU “San Giovanni di Dio e Ruggi D’Aragona”, UTIC, Salerno, Italy
3 University of Naples SUN, Department of Psychiatry, Napoli, Italy
∗ Corresponding author.
Introduction Depression increases the risk of ischemic heart dis-
ease in healthy people and impairs the outcome of heart diseases.
The endogenous stress response system, including the autonomous
nervous system and the hypothalamus-pituitary-adrenal (HPA)
axis, seems to play a primary role in the connection between
depression and ischemic heart disease.
Objectives and aims We investigated concomitantly the HPA axis
and the sympathetic nervous system (SNS) activities in patients
withan acute coronary syndrome (ACS), in relation to the presence
of concomitant or ongoing depression.
Methods Fifty men and women consecutively admitted to the
inpatient cardiologic unit of the Department of Medicine of the
University of Salerno with a diagnosis of ACS underwent saliva
sample collection at awakening and 15, 30 and 60min after awak-
ening within the 7th day of their ACS attack. They were screened
for comorbid depression at admission and after 1, 3 and 6 months
after their ischemic event. Saliva cortisol and alpha-amylase levels
were measured.
Results Major depression was diagnosed in 10% of the patients.
As a group, they exhibited a cortisol awakening response (CAR)
significantly enhanced as compared to subjectswithout depression.
Alpha-amylase levels did not differ significantly between the two
groups.
Discussion Present findings suggest that an increase of HPA axis
activity, as measured by CAR, in the first days after an ischemic
cardiac event is associated with the risk of major depression. The
extent to which this may predict also the cardiac outcome is cur-
rently under evaluation.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV488
Facing depression with botulinum
toxin: Literature review
M. Cátia Alves ∗, G. Sobreira , M.A. Aleixo , J.M. Oliveira
Centro Hospitalar Psiquiátrico de Lisboa, Psychiatry, Lisbon, Portugal
∗ Corresponding author.
Introduction Affecting over 120 million people, major depressive
disorder (MDD) is characterized by low mood, lack of interest and